Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Labopin

Showing results (181-190 of 443) with videos related to

Pageof 45
Sort By:
Haematologica|August 27, 2016
Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemiaMohamad Mohty, Florent Malard, Didier Blaise, et al.
American Journal of Hematology|July 24, 2018
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemiaFrancesco Saraceni, Eric Beohou, Myriam Labopin, et al.
Bone Marrow Transplantation|February 2, 2022
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Xiao-Jun Huang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2019
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationOlle Ringdén, Ariane Boumendil, Myriam Labopin, et al.
Bone Marrow Transplantation|May 16, 2019
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndromeThierry Guillaume, Florent Malard, Leonardo Magro, et al.
American Journal of Hematology|November 21, 2018
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remissionXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Bone Marrow Transplantation|October 25, 2019
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMTThomas Heinicke, Myriam Labopin, Emmanuelle Polge, et al.
American Journal of Hematology|July 14, 2020
Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemiaBhagirathbhai Dholaria, Myriam Labopin, Emanuele Angelucci, et al.
Bone Marrow Transplantation|June 1, 2021
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMTJohanna Waidhauser, Myriam Labopin, Jordi Esteve, et al.
Frontiers in Immunology|July 24, 2019
Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working PartiesRaffaella Greco, Myriam Labopin, Manuela Badoglio, et al.
Pageof 45

Showing results (181-190 of 443) with videos related to

Sort By:
Pageof 45
Haematologica|August 27, 2016
Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemiaMohamad Mohty, Florent Malard, Didier Blaise, et al.
American Journal of Hematology|July 24, 2018
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemiaFrancesco Saraceni, Eric Beohou, Myriam Labopin, et al.
Bone Marrow Transplantation|February 2, 2022
Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMTArnon Nagler, Myriam Labopin, Xiao-Jun Huang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2019
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationOlle Ringdén, Ariane Boumendil, Myriam Labopin, et al.
Bone Marrow Transplantation|May 16, 2019
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndromeThierry Guillaume, Florent Malard, Leonardo Magro, et al.
American Journal of Hematology|November 21, 2018
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remissionXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Bone Marrow Transplantation|October 25, 2019
Fludarabine/busulfan versus fludarabine/total-body-irradiation (2 Gy) as conditioning prior to allogeneic stem cell transplantation in patients (≥60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMTThomas Heinicke, Myriam Labopin, Emmanuelle Polge, et al.
American Journal of Hematology|July 14, 2020
Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemiaBhagirathbhai Dholaria, Myriam Labopin, Emanuele Angelucci, et al.
Bone Marrow Transplantation|June 1, 2021
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMTJohanna Waidhauser, Myriam Labopin, Jordi Esteve, et al.
Frontiers in Immunology|July 24, 2019
Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working PartiesRaffaella Greco, Myriam Labopin, Manuela Badoglio, et al.
Pageof 45